Antti Ylikorkala

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com

For more than 30 years, our mission has been to improve provider network management and in turn, help people across America receive the information and care they deserve. Our Provider Network Management platform brings trust, transparency, and confidence in the process of measuring, managing, and monitoring your provider networks. We partner with both providers and healthcare organizations to address two of the biggest issues facing the healthcare industry today: accessible networks and accurate provider directories. Through our BetterDoctor Exchange, we make it easy for providers to verify and update their data. We deliver the accurate provider data in our enterprise solution to enable health plans, health systems, payers, and healthcare organizations to maintain adequate networks & accurate provider directories. We help you maintain compliance with the federal and state regulator requirements, streamline internal processes across your organization, and allow you to provide your members with convenient access to the care they are looking for. Our Quest Analytics Family includes over 400 of America’s healthcare organizations, as well as more than 500,000 providers, nationwide. We honor and cherish every relationship we have with our business partners. As we continue to lead the industry in Provider Network Management, we welcome the opportunity to strategize with you and your team about how we can assist you with these same critical matters. Lets come together to transform the future of healthcare! Better Data. Better Networks. Better Experience.

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com